Carregant...
IMMU-17. REDUCING THE EX VIVO MANUFACTURING TIME OF EGFRVIII-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS IMPROVES PHENOTYPE AND DEMONSTRATES POTENT ANTI-GLIOMA FUNCTION IN VIVO
Chimeric antigen receptor (CAR) T-cell therapy for glioma has been developed that targets EGFRvIII, HER2, EphA2, and IL13Rα2 antigens. Epidermal growth factor receptor variant III (EGFRvIII) is an attractive target for CAR therapy because its expression is tumor-restricted. Non-viral manufacturing o...
Guardat en:
| Publicat a: | Neuro Oncol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692930/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.476 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|